Anavex Life Sciences Corp. (AVXL) Stock Forecast
AVXL analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $20.00 average of analyst targets
- Upside to target
- +1,426.7% from the latest close
- Next earnings
- November 24, 2026 EPS estimate $-0.11
- 52-week range
- $1.31 – $9.36
AVXL analyst ratings
1 analystsNumber of analysts at each rating.
AVXL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AVXL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$0.12 | −$0.12 | −$0.12 | −$0.06 | −100.0% | 1 |
| Current fiscal year (FY2026) | −$0.33 | −$0.33 | −$0.33 | −$0.54 | +38.9% | 1 |
| Next fiscal year (FY2027) | −$0.55 | −$0.55 | −$0.55 | −$0.33 | −66.7% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AVXL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Dec '26) | $0 | $0 | $0 | — | — |
| Current fiscal year (FY2026) | $0 | $0 | $0 | 0.0% | — |
| Next fiscal year (FY2027) | $0 | $0 | $0 | 0.0% | 1 |
AVXL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AVXL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | $0.00 | $0.00 | −$0.12 | −$0.12 | −$0.12 | — | 0 up · 0 down |
| Current fiscal year (FY2026) | −$0.33 | −$0.33 | −$0.33 | −$0.33 | −$0.33 | +1.5% | 2 up · 0 down |
| Next fiscal year (FY2027) | −$0.14 | −$0.14 | −$0.14 | −$0.14 | −$0.55 | +292.9% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AVXL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AVXL beat in 10 of 12.
What analysts expect from AVXL
1 analysts cover Anavex Life Sciences; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $20.00, 1,426.7% above the latest close of $1.31. Analysts expect earnings of −$0.33 per share for FY2026, +38.9% from a year earlier. For FY2027 the average estimate is −$0.55 per share. Anavex Life Sciences beat the EPS estimate in 10 of the last 12 quarters.
Related: AVXL income statement, AVXL key metrics, AVXL chart. See the AVXL stock overview for the latest quote and news.
AVXL forecast FAQ
What is Anavex Life Sciences's price target?
The average analyst price target for Anavex Life Sciences is $20.00, 1,426.7% above the latest close of $1.31.
Is Anavex Life Sciences a buy, hold or sell?
Of 1 analysts covering Anavex Life Sciences, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Anavex Life Sciences's EPS forecast?
Analysts forecast −$0.33 per share for FY2026 (range −$0.33 to −$0.33); for FY2027 the estimate is −$0.55.
When does Anavex Life Sciences report earnings?
Anavex Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 24, 2026 before the market opens; the EPS estimate is $-0.11.
Does Anavex Life Sciences usually beat earnings estimates?
Anavex Life Sciences reported EPS at or above the analyst estimate in 10 of the last 12 quarters.